Idorsia (OTCMKTS:IDRSF – Get Free Report) will likely be posting its results before the market opens on Tuesday, April 28th. Analysts expect Idorsia to post earnings of ($0.2328) per share and revenue of $54.1170 million for the quarter.
Idorsia Price Performance
Shares of OTCMKTS IDRSF opened at $4.32 on Friday. Idorsia has a fifty-two week low of $1.00 and a fifty-two week high of $5.82. The firm’s 50-day simple moving average is $4.35 and its 200 day simple moving average is $4.57.
Idorsia Company Profile
Idorsia Ltd is a Swiss biopharmaceutical company founded in 2017 as a spin-off from Actelion following its acquisition by Johnson & Johnson. Headquartered in Allschwil, Switzerland, Idorsia focuses on the discovery, development and commercialization of innovative small-molecule therapeutics. The company’s R&D efforts span multiple therapeutic areas, including neuroscience, cardiovascular and immunology, with the goal of addressing unmet medical needs through novel mechanisms of action.
Among Idorsia’s lead products is daridorexant, a dual orexin receptor antagonist developed for the treatment of insomnia.
Featured Articles
Receive News & Ratings for Idorsia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idorsia and related companies with MarketBeat.com's FREE daily email newsletter.
